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ABSTRACT 
The purpose is to provide an overview on the incidence of gallstone disease in patients with various types of inherited (chronic) hemolytic diseases 
at risk of cholelithiasis/choledocholithiasis with particular emphasis on its pathogenesis, genetic, risk factors and management. A detailed 
electronic literature search to determine the source of materials for this review article was done. The reported incidences of gallstones and 
choledocholithiasis vary according to the different types of inherited hemolytic diseases and the ethnicity of the studied populations. To date, no 
review article summarises the incidences of cholelithiasis in patients with various inherited haemolytic diseases was published. Regular ultrasound 
examination for the presence of gallstones recommended in patients with inherited haemolytic anaemias, particularly those with additional risk 
factors recommended. Further studies for evaluating the reasons for the higher incidence of cholelithiasis in thalassemia major and sickle cell 
anemia compared to hereditary spherocytosis; the effect of co inheritance of alpha thalassaemia on decreasing bilirubin level in patients with sickle 
cell disease and beta thalassaemia; the effect of the co inheritance of UGT1A1 and ABCG8 gene mutation on the incidence of gallstones in other blood 
diseases such as Hb-H disease, autoimmune haemolytic anaemias, congenital dyserythropoietic anaemia, hereditary elliptocytosis, Southeast Asian 
Ovalocytosis, glucose-6-phosphate and pyruvate kinase deficiency are recommended. Evaluation of the potential role of the solubility of the mutant 
proteins and haemoglobin subunit in the red blood cells as an additional mechanism for the development of gallstones in patients with inherited 
haemolytic anaemias recommended. 
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INTRODUCTION 
In reviewing the literature through 2014, the reported incidences of 
gallstones (cholelithiasis) and stones formed in the hepatic ducts 
(choledocholithiasis) vary according to the different types of 
inherited (chronic) hemolytic diseases and the ethnicity of the 
studied populations. The reported incidences of gallstones in 
different types of inherited hemolytic diseases are; 4-85 % in Sickle 
Cell Anaemia (Hb-SS), 29 % in Sickle Cell trait (Hb-AS), 23 % in 
Sickle Cell Hemoglobin-C (Hb-SC), 12 % in Hb S-B-Thalassaemia, 4-
61 % in Hereditary Spherocytosis, 30->80 % in β-thalassaemia 
Major, 23-57 % in β-thalassaemia Intermedia, 21 % in β-
thalassaemia Minor (Trait). Chronic hemolysis leads to increased 
bilirubin excretion and pigment gallstones formation, thus patients 
who are homozygous have the higher incidence of gallstones 
development than those who are heterozygous for that particular 
gene defect and disease, and there is a general trend in this 
direction. The incidence of gallstones increased in the last years [1]. To 
date, no review article summarises the incidences of cholelithiasis in 
patients with various inherited haemolytic diseases. We aim to increase 
the awareness of the incidence of gallstone disease with particular 
emphasis on its pathogenesis, genetics and risk factors and management 
in patients with various inherited chronic haemolytic diseases. A detailed 
electronic literature search to determine the source of materials for this 
report was done. Keywords used for websites searching were 
“Gallstones, cholelithiasis, choledocholithiasis, hemoglobinopathies and 
haemolytic disease”. The Pro Quest Hospital Collection and NCBI search 
were the principal sources of information. All searches limited to 
research published in English. In addition, the Google Scholar search 
engine used in the search. The resulting literature involved over 700 
peer-reviewed journal articles. Out of the total 100 reviewed and 
analysed articles, 62 selected articles were included in this report. In 
addition, review articles were included in the references because they 
provided contextual material for the review.  
Aetiology and pathogenesis 
The pathogenesis of biliary calculi in the various inherited chronic 
haemolytic anaemias is not understood clearly. In haemolytic 
anemias, the liberated hemoglobin is broken down, and its heme 
component is eventually, degraded into bilirubin by the liver. The 
development of pigmented gallstones due to chronic hemolysis is 
age-dependent. Etiologically, cholelithiasis is divided into three 
groups; hemolytic, other known etiology, and idiopathic. A 30% of 
all gallstones in children are due to haemolytic diseases such as 
sickle-cell disease, hereditary spherocytosis and thalassemia. In 
about 30% of cases, gallstones are due to another known etiology 
such as cholestasis, chronic liver disease, prolonged fasting and ileal 
disease or resection. In 40% of cases, gallstones are idiopathic 
mainly in adults and adolescent girls [1]. Cholesterol gallstones 
(green, white, or yellow stones) (pure and mixed) that are made 
mostly of cholesterol (70-80%), plus calcium salts and bilirubin 
compounds (20-30%). The pigmented stones (black or brown) 
contain less than 20% cholesterol and are composed mainly of 
bilirubin and calcium salts. Mixed gallstones composed of a mixture 
of the two gallstone types (fig. 1). 
Mixed gallstones are the commonest stones in adults, and the 
pigment stones are more common in children. Cholesterol 
supersaturation of bile together with biliary stasis predisposes 
to cholesterol gallstone formation. Pigmented stones formed due 
to supersaturation of bile with calcium bilirubinate as in 
hemolytic disorders. Biliary sludge composed of mucin; calcium 
bilirubin and cholesterol crystals commonly associated with 
sickle-cell disease (fig. 2). The biliary sludge may resolve 
spontaneously or may progress to gallstone development. 
Persistent sludge gives rise to biliary complications (such as 
obstruction or infection). Bilirubin converted in the hepatocytes 
to bilirubin monoglucuronide or di glucuronide by several 
classes of the enzyme glucuronosyl transferase.  
The poorly soluble bilirubin is frequently present in the cholesterol 
stones as the bilirubin precipitates in the gallbladder and forms 
bilirubin stones (fig. 3). Unconjugated as well as defectively 
conjugated bilirubin enhances the cholesterol crystallization by 
direct interaction with biliary lipid or indirect alteration of biliary 
lipid or both [2]. 
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Fig. 1: (A) Cholesterol, (B) pigmented (Source: www. med. umich. edu) and (C) mixed stones (Source: health-fts.blogspot.com) 
 
 
Fig. 2: (A) Biliary sludge (Source: http://www.radiologytutorials.com), (B) Multiple gallstones (Source: 
http://www.rcstn.net/marisa.bush) 
 
It has formulated by Dewey KW and Grossman H. in 1970 [3] that 
the incidence of cholelithiasis in hereditary spherocytosis is higher 
compared to beta thalassemia major and sickle cell anemia. The 
proposed higher rate attributed to the concentration of hemoglobin 
and total hemoglobin mass. In hereditary spherocytosis, an 
abnormality in red cell shape is secondary to changes in the cell 
membrane. The spherocytic cells despite their relatively small size, 
contain normal to increased amounts of hemoglobin. In both 
thalassemias major and sickle-cell anemia, the primary defect is 
failure to synthesize normal adult haemoglobin either by the 
inability to produce beta chains or by abnormal amino acid 
substitutions, respectively. As a result, the red blood cells in 
thalassemia major are hypochromic and microcytic, thereby 
containing less hemoglobin; whereas in sickle-cell anemia, the total 
cell mass may be less because of the abnormal red cell shape. Thus, 
for each red blood cell hemolyzed, there is a greater amount of 
bilirubin produced from the cell of hereditary spherocytosis [3]. This 
proposal is suboptimal to explain the higher reported incidences of 
gallstone disease in beta thalassemia major and sickle cell anemia 
compared to that in hereditary spherocytosis. Moreover, genetics 
and other risk factors are proven to contribute toward the 
development and incidences of gallstone disease in various 
inheritedchronichemolytic disease. However, the practice of using 
the non-invasive and sensitive detection technique (ultrasound 
scan) and the longer survival of patients with inherited hemolytic 
diseases might explain the higher incidences of gallstone disease in 
beta thalassemia major and sickle cell anemia compared to that in 
hereditary spherocytosis. According to the physiology of 
macrophages and their role in the cellular protein catabolism, 
unstable globin is polyubiquitinated and degraded via the 
proteasome. If ubiquitin-proteasome activity is insufficient, unstable 
globin forms insoluble aggregates that serve as a substrate for macro 
autophagy. Chaperones are involved in refolding unstable globin or 
in targeting unstable globin for degradation. Accumulation of 
unfolded proteins activates autophagy (fig. 3). The complete 
breakdown of proteins requires the action of proteinases capable of 
degrading proteins to small peptide fragments, and peptidases that 
hydrolyze these peptides to amino acids [4]. However, does 
gallstone disease is pertinent to the broader framework of protein-
aggregation or metabolism disorders?. This question requires to 
know the sequence of proteolytic events in detail particularly in 
hematological diseases with insoluble/unstable globins [5, 6]. 
Additional studies both in laboratories and in the clinics will be 
necessary to appraise with accuracy the role of hemoglobin degradation 
products (such as hemorphins) in physiology or pathology [7]. 
Evaluating the role of the altered solubility of the mutated proteins and 
haemoglobin subunit in the red blood cells could provide additional 
information for the mechanism of the gallstones development in patients 
with inherited hemolytic diseases. 
 
 
Fig. 3: Mechanism of the extravascular hemolysis and gallstones 
development 
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Genetic and risk factors 
Up to one-third of gallstones may be related to genetic factors.  
1- Ethnicity: it is significant risk factors mainly in the paediatric 
population. 
2- Mutation in the uridine diphosphate-glucuronosyltransferase 
gene (UGT1A): This gene is a nested gene complex comprising nine 
transcriptional units, each encoding a specific isoform of the enzyme. 
UGT1A1 is responsible for bilirubin glucuronidation. The 2-bp (TA) 
insertion within the promoter of theUGT1A1, is associated with 
Gilbert syndrome. The promoter polymorphisms in the UGT1A1 gene 
resulted in excessive bilirubin production and associated with 
unconjugated hyperbilirubinemia. The latter appear to be a risk 
factor for symptomatic gallstones in subjects with sickle cell anemia 
(SCA) and hereditary spherocytosis [8]. It is reported that, children 
with SCA and the 7/7 promoter UGT1A1 genotype had a significantly 
higher mean bilirubin level than those with the 6/6 or 6/7 
genotypes and were more likely to have had a previous 
cholecystectomy [9,10]. The presence of the 7/7 UGT1A1 genotype 
may also adversely affect the ability of hydroxyurea to prevent 
gallstone formation in SCA. Carriers of the 7/7 genotype had 
bilirubin levels more than 3 mg/dL despite full-dose hydroxyurea 
therapy while those with the 6/6 genotype had normal bilirubin 
levels following treatment with this agent [11]. Coinheritance of 
Gilbert syndrome increases the risk of developing gallstones in 
patients with hereditary spherocytosis. UGT1A1 gene promoter 
polymorphism is also a major genetic risk factor modifying the 
frequency and age-at-onset of cholelithiasis in patients with SCA 
[12]. The individual susceptibility to form gallstones from TA 
insertion in the TATA-box of the UGT1A1 promoter should be 
considered during the follow-up of patients with different forms of 
inherited (eg, thalassemia, intraerythrocytic enzymatic deficiency) 
or acquired (eg, autoimmune hemolytic anemia, hemolysis from 
mechanical heart valve replacement) chronic hemolysis. 
Homozygosity of the (TA)7 allele (also known as UGT1A1*28) has 
been implicated in Gilbert’s syndrome and the unusually high 
unconjugated bilirubinemia observed in individuals with various 
forms of inherited chronic hemolysis: heterozygous β-thalassemia, 
β-thalassemia intermedia, neonatal jaundice associated with 
glucose-6-phosphate dehydrogenase deficiency, hereditary 
spherocytosis and sickle cell anemia [12]. 
3- Mutation in the ATP-binding cassette transporter sub-family C 
member 8 (ABCG8) gene significantly increases the risk of gallstones 
by causing the cholesterol pump to work continuously at a high rate. 
A single gene, however, does not explain the majority of cases, so 
multiple genes and environmental factors play an intricate role.  
4- Multiple blood transfusions: In patients who periodically 
receive blood transfusions, hemolysis of the transfused cells may 
supplement the chronic endogenous blood destruction as a factor in 
the formation of gallstones [13].  
5- High rates (20% by age of four years) of recurrent biliary tract 
obstruction in children with the sickle cell disease reported [14]. 
6- Obesity: With the prevalence of childhood obesity on the rise, 
there is a need to be more aware of obesity-related comorbidity 
including gallbladder disease. No clear link between the diet and risk 
for cholelithiasis, though foods high in cholesterol and low in fiber 
may increase the risk [15]. 
7- Inefficient and infrequent gallbladder contractions, which 
allow bile to sit in the gallbladder for long periods of time, resulting 
in an over concentrated bile that is conducive to stone formation 
[16].  
8- Other risk factors include liver cirrhosis and biliary tract 
infections, trisomy 21 in patients with sickle cell disease and 
extensive small bowel resection requiring total parenteral nutrition 
[13].  
Epidemiology 
A prominent feature of children with chronic haemolytic anemia is 
the development of premature bilirubin gallstone disease and biliary 
tract inflammation. Of interest is the variation with the age of 
incidence of cholelithiasis in the haemolytic anemias(table 1). As 
patients with hemolytic anemia grow older, gallstones are more 
likely to develop. 
 
Table 1: Prevalence (%) of gallstones according to the type of inherited hemolytic diseases, age group and population 
Type of inherited hemolytic diseases [%] Age group Population Gallstones (%) Ref.  





Jamaican 30/226 (13) 14 
Brazilian 72/143 (50) 48 
USA (34-70) 17 
African (4-25) 17 
KSA (8) 17 
KSA 60/305 (20) 47 
Sudan 30/261 (11) 22 
USA 4/47 (9) 3 
Italy (15) 50,51 
Italy/Cuba 17/27 (63) 53 
Adults 
 
Jamaican 96/311 (31) 13 
UK 55/95 (58) 17 
KSA 90/170 (53) 56 
Italy (80) 50,51 
India 8/80 (10) 54 


















Sickle Cell Trait 
(Hb-SA) 
[0-29] 
Children Jamaican 00/25 14 
Adults Cameron  26/90 (29) 21 
Both USA 3/15 (20) 57 




Jamaican 4/138 (3) 14 




USA 3/15 (20) 34 
Jamaican 18/167 (11) 13 
UK 24/95 (17) 17 
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Nigeria 8/24 (33) 62 
Nigeria 1/10 (10%) 61 
Hb S-B-Thal 
[12] 





Brazil 17/63 (27) 41 
 18/44 (41) 50 
Italy/Cuba 7/27 (26) 53 
 USA 1/25 (4) 3 
USA 6/13 (46) 3 
Adult 
 
USA 45/74 (61) 3 
Both 
 
India 26/70 (37) 38 
β-thalassaemia Major  
[30->80] 
Children [11-50] Italy 257/858(30) 27 
Italy (50) 52 
Italy/Cuba 3/27 (11) 53 
USA 7/56 (13) 3 
Adults 
 
Italy (>80) 52 
USA 6/26 (23) 3 
USA 6/11 (55) 3 
Both 
 
Italy  52/261 (20) 55 
Italy 257/858 (30) 59 
β-thalassaemia Intermedia 
[23-57] 
Adults Sri Lanka 18/79 (23) 29 
Both Italy 148/261 (57) 55 
β-thalassaemia Minor (Trait) 
 [21] 
Adults Italy  30/143 (21) 27 
 
1-Sickle Cell Disease (SCD): Most patients are asymptomatic. 
Symptomatic biliary tract disease is difficult to diagnosis in patients with 
SCD, who frequently can have acute abdominal pain, fever and jaundice, 
as symptoms of vaso-occlusive crisis. Distinguishing acute cholecystitis 
from the sickle hepatic crisis may be difficult because of their similar 
clinical presentations. Early recognition of this entity is essential to avoid 
life-threatening complications. The prevalence of pigmented gallstones 
in SCD directly related to the rate of hemolysis [17].  
a- Sickle Cell Anaemia (Homozygous): Pigmented gallstones are 
seen in two third of patients, particularly in young children. Gallstones 
in children as young as 3-4 years of age found in about 70 percent of 
patients (table 1)[18-23]. In a study of 509 adult patients with SCD, 48 
percent of patients aged 18 to 47 years and 69 percent of those with 
more than 47 years of age had undergone cholecystectomy [24]. 
However, the frequency of gallstones in patients with sickle cell 
anaemia varies according to other different studies [25-29]. 
b- Sickle Cell Trait (Heterozygous): The reported incidence of 
gallstones in patients with sickle cell trait is low (table 1)[20]. 
c- Hb-SC and Hb-S B-Thalassaemia syndrome: The risk of 
gallstones is low in patients with HbSC disease and HbSß-
thalassemia [21]. 
d- Coinherited alpha thalassaemia causes decreased bilirubin 
level in patients with sickle cell disease. The incidence of gallstones 
and bilirubin levels strongly associated with the number of the 
UGT1A1promoter (TA) repeats [22, 23]. 
2-Beta-Thalassaemias: Hemolysis and extra medullary 
erythropoiesis lead to the more prominent hepatomegaly in beta 
thalassaemias than in other causes of inherited haemolytic anemia. 
a- Beta-Thalassaemia Major. Two-thirds of patients have multiple, 
calcified bilirubin stones by the age of 15. However, cholecystitis or 
cholangitis are rare. Adult patients with beta-thalassemia major 
have gallbladder dysmotility with delayed small bowel transit and 
autonomic dysfunction that together with hyperbilirubinemia 
contribute to the pathogenesis of pigment gallstones/sludge in beta-
thalassemia major [30]. 
b- Beta Thalassaemia Minor (Trait): Characterized by chronic 
ineffective erythropoiesis and variable levels of serum bilirubin. 
Thalassaemia minor represent a risk factor for gallstones, but the 
associated gilbert mutation further increases this risk. Carriers of 
beta thalassaemia havesignificantly higher risk of gallstone 
formation than the normalpopulation [31]. 
c- Beta-Thalassaemia Intermedia (Hb-E β-Thalassaemia): Chronic 
hyper bilirubinaemia, gallstones formation and gallbladder disease 
are unusually frequent in people with haemoglobin E β-
thalassaemia. 
This category is the most common of beta-thalassaemia of 
intermediate severity in the world and represents an important 
health problem for populations of the Indian subcontinent and 
Southeast Asia [32, 33]. 
3-Hereditary Spherocytosis (HS): Bilirubin stones found in 50 % of 
patients with HS between 30 and 50 years of age, even in those 
with very mild forms of the disease. Gallstones have reported 
during infancy, but they are uncommon in very young children. 
Pigmented gallstones form as early as 4-5 years old children, and 
at least 50 % of unsplenectomized patients ultimately form 
gallstones, although they may be asymptomatic. The incidence of 
gallstones is uncommon before age ten but is present in at least 
one-half of adults with more severe hemolytic disease [34]. The 
development of jaundice due to gallstones improves the hemolytic 
process and normalizes osmotic fragility [35]. The increased 
membrane surface area due to the abnormal plasma lipid profile 
normalizes the previously reduced surface area-to-volume ratio 
due to loss of membrane surface area in the spherocytes. The 
incidence of gallstones is increased further if the patient with HS 
co-inherits the genetic defect resulting in the diminished activity 
of the bilirubin conjugating enzyme uridine diphosphate-
glucuronyltransferase (i.e., Gilbert syndrome). In a study of 102 
children from southern Italy with mild to moderate HS, gallstones 
were found in 12, 26, and 48 percent of children who were normal, 
heterozygous, or homozygous for the Gilbert syndrome mutation, 
respectively. However, no significant difference in the age of onset 
of gallstones or the degree of hemolysis, as measured by average 
reticulocyte count [36]. 
4-Other chronic haemolytic anemias: The gallstones could also occur 
in patients with other inherited haemolytic anaemia such as Hb-H 
disease, autoimmune haemolytic anaemias, congenital 
dyserythropoietic anaemia, hereditary elliptocytosis, Southeast 
Asian Ovalocytosis and pyruvate kinase deficiency [8,9]. Prevalence 
of gallstones in these blood disorders in not well known. 
Management 
Silent gallstones require no intervention. Laparoscopic 
cholecystectomy can be safely performed, but associated common bile 
duct stones first require endoscopic retrograde cholangiopancreato 
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graphy (ERCP) [37-39]. In hereditary spherocytosis, cholecystectomy 
is indicated for symptomatic gallstones with recurrent cholecystitis or 
biliary colic. Combined prophylactic splenectomy and cholecystectomy 
provide a substantial gain in life expectancy for young patients and 
adults with mild HS and gallstone [40, 41]. However, the use of 
concomitant splenectomy is controversial and considered on an 
individual basis, weighing the severity of haemolytic anemia versus 
the post-splenectomy risks [42-45]. Elective cholecystectomy 
considered in patients with sickle cell disorders and gallstones-related 
symptomatology [46]. After a decision is made to perform 
cholecystectomy, the gold standard surgical strategy is the 
laparoscopic procedure. Laparoscopic cholecystectomy is 
recommended because it associates with a shorter hospital stay and 
lower rates of postoperative complications. Prior to surgery, blood 
transfusion therapy is recommended and aimed to get the hemoglobin 
up to 100 g/l to prevent potentially life-threatening Intra-and 
postoperative complications [47]. A multicenter, randomized trial 
compared observation with blood transfusion therapy no more than 
ten days prior to surgery [48]. In the latter multicenter study, a) out of 
the 70 enrolled patients, complications were more common in 
observation group than in transfusion group (39 versus 15 %), b) 
severe complications were more common in the observation group 
(30 versus 3 percent), c) acute chest syndrome occurred in nine of the 
participants in the observation group and one in the transfusion group, 
d) hemoglobin-S decreased to at least 30 % and total haemoglobin be 
increased at least 110 g/l to avoid sickling during the postoperative 
period. Blood transfusion considered for individuals with Hb-SS and 
Hb less than 90 g/l undergoing cholecystectomy. For individuals 
with Hb-SS or other types of SCD who have baseline hemoglobin 
greater than 90 g/l, partial exchange transfusion and adequate 
hydration are considered to avoid the development of 
hyperviscosity syndrome. Red blood cell pheresis designed to 
decrease the Hb-S level to<30 percent does not confer any 
advantage over simple blood transfusion therapy and preferably 
avoided, except under special circumstances [49-54]. During the 
surgery and the recovery period, hypotension, dehydration, hypoxia, 
hypothermia and acidosis should be prevented [55]. Elective 
cholecystectomy is recommended for patients with hepato biliary 
symptoms and biliary sludge only [56]. Any symptomatic gallstone 
should be treated by cholecystectomy because the accelerated 
hemolysis in beta thalassaemia leads to the formation of gallstones. 
Since cholecystitis is life-threatening in any splenectomized patient, 
inspection of the gallbladder in any patient who is undergoing 
splenectomy recommended [31]. 
Conclusions and recommendations 
1. Regular ultrasound examination for the presence of gallstones 
recommended in patients with inherited haemolytic anaemias, 
particularly those with additional risk factors.  
2. Further studies for evaluating the reasons for the higher 
incidence of cholelithiasis in beta thalassemia major, sickle cell 
anaemia compared to hereditary spherocytosis recommended. 
3. Evaluation of the potential role of the solubility-changing 
mutations expressing low-solubility haemoglobin subunit in the red 
blood cells as an additional mechanism for the development of 
gallstones in patients with inherited haemolytic 
anaemiasisrecommended. 
4. The question whether gallstone disease is pertinent to the 
protein-aggregation or metabolism disorders requires toknowthe 
sequence of proteolytic events in detail particularly in hematological 
diseases with unstable globins.  
5. Additional studies both in laboratories and in the clinics will be 
necessary to appraise the role of haemoglobin degradation products 
(such as hemorphins) in physiology or pathology recommended. 
6. The effect of coinheritance of alpha thalassaemia decreasing 
bilirubin level in patients with sickle cell disease and beta 
thalassaemiarequire further evaluation.  
7. The effect of the coinheritance of uridine diphosphate-
glucuronosyltransferase and ABCG8 gene mutation on the incidence 
of gallstones in other blood diseases (such as Hb-H disease, 
autoimmune haemolytic anaemia, congenital dyserythropoietic 
anaemia, here ditary elliptocytosis, Southeast Asian Ovalocytosis, 
glucose-6-phosphate dehydrogenase and pyruvate kinase 
deficiency) need to be formulated. 
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